Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839914 | 0.91 | KDM1A (0.33) | CHRNA7HRH3CYP2D6KCNH2KDM1A | |
| SCHEMBL841019 | 0.89 | HRH3 (0.35) | HRH3CYP2D6KCNH2KDM1AALDH1A1 | |
| SCHEMBL24827854 | 0.87 | OPRM1 (0.43) | — | |
| SCHEMBL24794287 | 0.87 | SHBG (0.37) | HRH3CYP2D6KDM1AALDH1A1 | |
| SCHEMBL24828014 | 0.87 | OPRM1 (0.43) | — | |
| SCHEMBL23696110 | 0.85 | ALDH1A1 (0.33) | CHRNA7HRH3CYP2D6KCNH2KDM1A | |
| SCHEMBL22901352 | 0.85 | OPRL1 (0.37) | HRH3CYP2D6KCNH2KDM4E | |
| SCHEMBL408517 | 0.84 | — | — | |
| SCHEMBL840364 | 0.84 | HRH3 (0.34) | CHRNA7HRH3CYP2D6KCNH2KDM1A | |
| SCHEMBL14769610 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| WO-2024151919-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240241099-A1 | METHOD FOR IDENTIFYING PI3 KINASE-ALPHA INHIBITORS | UNIVERSITÄT BASEL (CH) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-7250413-B2 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CHRNA7 4011/4885HRH3 3552/4885CYP2D6 993/4885 |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | CHRNA7 3438/4885HRH3 1544/4885CYP2D6 1284/4885 |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | CHRNA7 1476/4885HRH3 440/4885CYP2D6 4388/4885 |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | CHRNA7 229/4885HRH3 335/4885CYP2D6 1238/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CHRNA7 4011/4885HRH3 3552/4885CYP2D6 993/4885 |
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | ADORA2A, ADORA3, ADORA1 | CHRNA7 354/4885HRH3 997/4885CYP2D6 1740/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | CHRNA7 3469/4885HRH3 454/4885CYP2D6 4337/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | CHRNA7 3045/4885HRH3 523/4885CYP2D6 3029/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHRNA7 4420/4885HRH3 3631/4885CYP2D6 3599/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | CHRNA7 4775/4885HRH3 4026/4885CYP2D6 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.